drugset / Trial / NCT07476898

Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window

NCT07476898

Phase 3 Not yet recruiting 864 enrolled First Hospital of China Medical University
RandomizedParallel-groupOpen-labelTreatment

Summary

To verify the efficacy and safety of intravenous tenecteplase (TNK) in patients with disabling minor stroke and large vessel occlusion (LVO) within a 4.5-24 hour time window.

Timeline

Start
2026-03-01
Primary completion
2028-07-01
Completion
2028-08-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aspirin Small molecule 100 mg Oral
Comparator Clopidogrel Small molecule 75 mg Oral
Subject Tenecteplase Protein / enzyme biologic 0.25 mg/kg Intravenous
Comparator Ticagrelor Small molecule 90 mg Oral

Indications